Reuters -- Dutch biotech company Crucell NV plans to kick off clinical Phase I studies of an experimental antibody-based flu drug next year amid strong government interest, its chief executive said on Tuesday.
Reuters -- Dutch biotech company Crucell NV plans to kick off clinical Phase I studies of an experimental antibody-based flu drug next year amid strong government interest, its chief executive said on Tuesday.
